Auer rods in mixed phenotype acute leukemia, T/myeloid: A report of three cases

1. INTRODUCTION

Mixed-phenotype acute leukemia (MPAL) is a rare and heterogeneous subtype of leukemias, comprising about 1.5-5.8% of acute leukemia [1-4]. MPAL can present as one blast population expressing different lineage specific markers or two distinct blast populations each of a different lineage. MPAL is often challenging to diagnose and manage, and the current diagnosis of MPAL mainly relies on morphology and immunophenotyping analysis by Flow cytometry. The identification of Auer rods in the blasts is traditionally considered as one of morphological features of myeloblasts and is diagnostic for acute myeloid leukemia. In this study, we describe 3 cases of MPAL with Auer rods identified in blasts and their clinicopathological features are discussed.

2. CASE REPORT

Case #1 was a 24-year-old woman with a 2-month history of weakness, skin rash (abdomen and face) and splenomegaly (17.8 cm in length). Blood count showed pancytopenia with hemoglobin of 67 g/L, red cell count of 2.05 x 10^12/L, white blood cell count of 1.89 x 10^9/L, and platelet count of 102 x 10^9/L. Peripheral blood smears revealed 67% circulating blasts. Bone marrow smears showed a hypercellular bone marrow with two types of blasts (Figure A): one blast population (45% of total cells) was large with moderate to abundant basophilic cytoplasm, sparse to numerous perinuclear azurophilic granules and frequent cytoplasmic vacuolation. Notably, Auer rods that appeared as single or multiple Auer rods were identified in subsets of blasts (Figure B). Another blast population (42% of total cells) was small to medium sized with scant agranular cytoplasm. Cytochemical stain for myeloperoxidase (MPO) was positive in 9% blasts, among which Auer rods were highlighted. The two distinct blast populations were also confirmed by flow cytometric analysis which showed two populations with a different immunophenotype: one blast population showed a myeloid phenotype, uniformly positive for CD33, CD34, HLA-DR, CD123, and CD11c, dimly positive for CD38, CD7, CD13, CD15, MPO, CD117, and CD64. They did not express cytoCD3, CD4, CD10, CD11b, CD14, CD19, CD35, cCD79a, CD300e and lysozyme. The second blast population showed a T-cell immunophenotype with high expression of CD2, cytoCD3, CD7, CD10, CD34, CD38, and CD123, dim expression of HLA-DR, CD33, CD13, CD5, and CD99. Other markers including sCS3, MPO, CD4, CD1a, CD8 and CD16 were negative. Cytogenetic analysis by G- and R-banding showed 46, XX [20]. No specific fusion genes were detected. Fluorescence in situ hybridization (FISH) was negative for KMT2A/MLL gene rearrangement and P53 gene deletion. Next generation sequencing (NGS) showed mutations in RELN Exon55 p.R2955C (variant allele frequency, VAF, 48.79%), TET2 Exon3 p.Q324H (VAF, 6.81%) and TP53 Exon9 p.N331D (VAF, 8.02%). Skin biopsy of abdominal erythema showed infiltration of T lymphoblasts, consistent with leukemia cutis. The patient was diagnosed as MPAL, T/myeloid with skin involvement. She was treated with VDCP + Ara-C regimen (Vincristine, Daunorubicin, Cyclophosphamide, Prednisone, Cytarabine) with a poor response.

Case #2 was a 34-years-old man with a reported history of T-lymphoblastic leukemia (T-ALL) diagnosed 15 months ago at an outside hospital. Fifteen months ago, he presented with “fever and coughing” and complete blood count showed leukocytosis with a white blood cell count of 100 x 10^9/L. Bone marrow study showed T-ALL with blasts positive for cytoCD3, CD5, CD7, CD8, CD13, CD33, CD34, CD38, HLA-DR, TdT and CD56 (partial). Cytogenetic karyotype was 46, XY [20]. He was diagnosed with T-ALL and treated with Hyper-CVAD regimen. The patient did not respond to the therapy and then switched to HD-MTX + Ara-C regimen and achieved morphological remission with 3% blast in bone marrow. He then received consolidation therapy composed of EA, TA, HD-MTX, VDCLP regimens (EA: Etoposide + Cytarabine, TA: Pirarubicin + Cytarabine, HD-MTX: high-dose Methotrexate, VDCLP: Vincristine, Daunorubicin, Cyclophosphamide, L-asparaginase, Prednisone). Nine months after the initial diagnosis, the patient had relapsed disease and treated with VCP, MA and EA regimens (VCP: Vincristine, Cyclophosphamide, Prednisone, MA: Mitoxantrone + Cytarabine, EA: Etoposide + Cytarabine) with a limited response. He was transferred to our hospital for further management. Physical examination showed multiple superficial lymphadenopathy. Bone marrow and peripheral blood smears showed numerous blasts that were intermediate or large sized with obvious Auer rods in a subset of blasts (Figure C-D). Immunophenotyping by flow cytometry showed one blast population, positive for cytoCD3, CD7, CD123, CD33, CD34, HLA-DR, TdT, CD56, CD11b, negative for CD2, CD4, CD8, CD5, and MPO. Although MPO was negative by flow cytometric analysis, special cytochemical stain showed 28% blasts positive for MPO (Figure E). To further confirm MPO positivity, electron microscopic study was performed and showed that 38% of blasts were positive for MPO (Figure F). Given that blasts expressed both T (cytoCD3) and myeloid (MPO) lineage defining markers, the diagnosis of MPAL, T/myeloid was rendered. Additional studies showed no BCR/ABL fusion or FLT3-ITD/TKD. No T-cell receptor or immunoglobulin heavy chain rearrangements was detected. The patient was treated with one cycle of HAD+VP regimen (HAD+VP: Homoharringtonine + Cytarabine + Daunorubicin + Vincristine + Prednisone) and showed no response.

Case #3 was a 51-years-old man presented with sore throat and weakness. Peripheral blood showed leukopenia with white blood cell count of 1.55 x 10^9/L. Bone marrow biopsy and smears showed acute leukemia with 80% blasts. Blasts were intermediate to large sized and about 20% of the blasts were identified to have Auer rods (Figure G-I). Flow cytometric analysis identified two blast populations: one...
predominant population (66% of nucleated cells) showed a myeloid immunophenotype, positive for CD117, CD34, CD38, HLA-DR, CD13, CD33, MPO, TdT (partial), CD123 (dim) and CD71 (dim), and negative for CD16, CD15, CD64, CD11b, CD56, CD36, CD14, CD19, cCD79a, and cytoCD3. Another minor blast population (5% of nucleated cells) showed a T-cell immunophenotype, positive for CD2 (partial), cytoCD3, cytoCD3. The differential diagnosis for MPAL is broad; AML mainly relying on morphology and immunophenotyping performance ambiguously, and its accurate diagnosis is often challenging, and currently there is no standard treatment regimen for MPAL. Previous studies indicated that acute lymphoblastic leukemia-like therapeutic approach followed by allogeneic stem cell transplant after first remission was favored in these patients [5-8], but novel therapeutic strategies need to be explored in the future.

The presence of Auer rods in MPAL had been very rarely reported in literatures [9-13]. Among these reported cases, all were Myeloid/T with the exception of one case being Myeloid/B. The 3 cases described in our study were also myeloid/T subtype. Thus, Auer rods are more commonly seen in myeloid/T of MPAL than myeloid/B subtype. The diagnostic pitfall is that the detection of Auer rods in acute leukemia does not warrant a diagnosis of AML. Careful morphologic evaluation as well as flow cytometric analysis is recommended to rule out MPAL, especially T/myeloid subtype.

3. DISCUSSION

In this study, we described 3 cases of MPAL with Auer rods and all were diagnosed as T/myeloid subtype following the criteria proposed in 2016 World Health Organization (WHO) classification and the European Group for Immunological Characterization of Acute Leukemias (EGIL). According to the WHO 2016, MPAL is a subtype of acute leukemia of ambiguous lineage, and its accurate diagnosis is often challenging, mainly relying on morphology and immunophenotyping performance by Flow cytometry. The differential diagnosis for MPAL is broad; AML with t(8;21) often expresses MPO as well as CD19 and other B cell markers such as PAXS, raising a possible diagnosis of MPAL, myeloid/B. The morphology and cytogenetic study to demonstrate RUNX1/RUNX1T1 translocation will clarify the diagnosis. For MPAL, T/myeloid, an important differential diagnosis is Early T-precursor lymphoblastic leukemia (ETP-ALL) as ETP-ALL often expresses myeloid markers. But by definition, ETP-ALL is negative for MPO. Thus positive MPO in blasts will rule out ETP-ALL.

Of these three cases, two (cases #1 and 3) showed two separate blast populations, myeloid and T respectively and Auer rods were identified in the myeloblasts. The remaining case (case #2) showed one blast population expressing both T and myeloid markers. All three cases showed non-complex karyotypes. Mutation analysis by NGS was done in two cases and both showed mutations associated with a poor prognosis. Two patients received induction chemotherapy and neither achieved a complete remission. The management of patients with MPAL is challenging and currently there is no standard treatment regimen for MPAL. Previous studies indicated that acute lymphoblastic leukemia-like therapeutic approach followed by allogeneic stem cell transplant after first remission was favored in these patients [5-8], but novel therapeutic strategies need to be explored in the future.

There is no trial registration in this study.

Acknowledgments

The authors would like to appreciate the funding of National Key Research and Development Program of China (2019YFC0840605), National Science and Technology Major Project (2017ZX09304024), National Natural Science Foundation of China (81830005, 81770181).

The authors would also like to thank Dr. Huijun Wang for performing flow cytometric analysis.
Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.lrr.2021.100236.

References

[1] MC Bene, G Castoldi, W Knapp, WD Ludwig, E Matutes, A Orfao, MB van’t Veer, Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia 9 (1995) 1783–1786.

[2] DK Weinberg, DA Arber, Mixed-phenotype acute leukemia: historical overview and a new definition, Leukemia 24 (2010) 1844–1851.

[3] L Yan, N Ping, M Zhu, A Sun, Y Xue, C Ruan, HG Drexler, RA Macleod, D Wu, S Chen, Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification, Haematologica 97 (2012) 1708–1712.

[4] W van den Ancker, M Terwijn, TM Westers, PA Merle, E van Beckhoven, AM Dräger, GJ Ossenkoppele, AA van de Loosdrecht, Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification, Leukemia 24 (2010) 1392–1396.

[5] JH Lee, YH Min, CW Chung, BK Kim, HJ Yoon, DY Jo, HJ Shin, SM Bang, JH Won, DY Zhang, et al., Prognostic implications of the immunophenotype in biphenotypic acute leukemia, Leuk Lymphoma 49 (2008) 700–709.

[6] XQ Xu, JM Wang, SQ Lü, I Chen, JM Yang, WP Zhang, XM Song, J Hou, X Ni, HY Qiu, Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population, Haematologica 94 (2009) 919–927.

[7] QF Liu, ZP Fan, MQ Wu, J Sun, XL Wu, D Xu, QI Jiang, Y Zhang, F Huang, YQ Wei, et al., Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimen, Ann Hematol 92 (2013) 679–687.

[8] EG Weir, M Ali Ansari-Lari, DA Batista, CA Griffith, S Fuller, BD Smith, MJ Borowitz, Acute bilineal leukemia: a rare disease with poor outcome, Leukemia 21 (2007) 2264–2270.

[9] ML Zucker, FV Flapp, JM Rachel, CA Murphy, RA Bohn, JL Boesch, LM McCann, JT Peterson, An adult case of acute biphenotypic leukemia with characteristic mixed morphology, Mo Med 90 (1993) 601–604.

[10] E Saragas, J Spector, G Chita, IA Dukes, R Bernstein, P Keene, BV Mendelow, Acute mixed-lineage leukemia involving myeloid and T-cell phenotypes. A case report, S Afr Med J 71 (1987) 529–530.

[11] P Reizenstein, M Beksc, P Biberfeld, B Christensson, B Lagerlöf, L Laurén, A Ost, A Porwit, Leukemic myeloblasts expressing lymphoid markers, Acta Haematol 74 (1985) 146–150.

[12] AH Cross, RM Goorha, R Nuss, FG Behm, SB Murphy, DK Kalwinsky, S Raimondi, GR Kitchingman, J Mirro Jr, Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity, Blood 72 (1988) 579–587.

[13] F Ferrara, O Finizio, CD Rosa, G Mele, V Mettivies, V Rametta, OA Spada, LD Vecchino, Acute Myeloid Leukemia Expressing T-Cell Antigens: Clinicopathological Report on Six Cases, Leuk Lymphoma 3 (1990) 217–222.

Yan Li, Wenrui Yang, Wei Wang, Dong Lin, Hui Wei, Ying Wang, Bingchung Liu, Huijun Wang, Jigang Xiao, Yongxin Ru, Shuxu Dong, Jianxiang Wang, Yingchang Mi.

* Yan Li and Wenrui Yang contributed equally to this work.

a State Key Laboratory of Experimental Hematology and National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China

b Tianjin Key Laboratory of Immunotherapy, Tianjin, China
c Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA

** Correspondence: Dr. Yingchang Mi, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.

*** Correspondence: Dr. Jianxiang Wang, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.

E-mail addresses: wangjx@ihcams.ac.cn (J. Wang), ychmi@ihcams.ac.cn (Y. Mi).